Stock Screener App

無料 -

インストール

1.42

1.43% 0.02

after-market

アフターアワーズ： 1.42

Acurx Pharmaceuticals Inc (ACXP)

概要ニュース株価時系列オプションチェーン Financials ディスカッション予測

Acurx Pharmaceuticals Inc (ACXP) 最新ニュース

Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan

Acurx (ACXP) Quarterly Scorecard: The Available Earnings Metric Delivers a Beat on the Day; Shares Fall 4.76% in Latest TradingHealthcare Earnings Report - vinanet.vn

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - The Globe and Mail

Acurx (ACXP) Price-Move Recap: Ends Down by 12.73% at $1.44 in the Latest Reading; Key Levels - vinanet.vn

Acurx Pharmaceuticals Receives FDA Conditional Acceptance - TradingView

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Yahoo Finance

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com Nigeria

Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView

Acurx Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 3ZO0 | US00510M2035 - marketscreener.com

Acurx Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | ACXP | US00510M2035 - marketscreener.com

Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade

Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang

Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey

Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan

ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView

Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan

Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

New patents cover Acurx antibiotics targeting DNA Polymerase IIIC - Stock Titan

Acurx and Leiden Researchers Seek 3D Structure to Guide MRSA Antibiotics - Stock Titan

ACXP Q2'26 Earnings: revenue estimate is 0 USD - TradingView

ACXP Q1 2026 Earnings: Narrower Net Loss Beats Expectations, Shares Rise 4.76%EPS Consistency Score - vinanet.vn

Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program - TradingView

FDA Provides Further Regulatory Guidance to A - Moomoo

Acurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reduction - Stock Titan

ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Continued R&D ExecutionEarnings Stability Report - vinanet.vn

ACXP Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline at a Pre-Revenue Stage - vinanet.vn

Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

ACXP|Acurx Pharmaceuticals Inc|Price:1.480|Chg%:-0.060 - TradingKey

ACXP|Acurx Pharmaceuticals Inc|Price:1.395|Chg%:-0.085 - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - tradingkey.com

TradingKey - TradingKey

Acurx Pharmaceuticals Inc (ACXP) Cash Flow - TradingKey

ACXP|Acurx Pharmaceuticals Inc|Price:1.435|Chg%:+0.015 - TradingKey

ACXP|Acurx Pharmaceuticals Inc|Price:1.450|Chg%:+0.010 - TradingKey

Acurx Pharmaceuticals (ACXP) Income Statement & Earnings - Moomoo

ACXP Q1 2026 Earnings: EPS Beats Estimates Amid Pre-Revenue Period, Stock Declines Moderately - vinanet.vn

Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr

Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Yahoo Finance Singapore

Acurx data: beneficial gut bacteria remain after repeated C. diff. courses - Stock Titan

Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView

Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Yahoo Finance

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com

Acurx Pharmaceuticals (ACXP) Slides 8.23% as Stock Tests Key Support at $1.38Relative Volume - dars.gov.et

Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - Ad-hoc-news.de

Acurx Pharmaceuticals (ACXP) Stock Analysis Report | Financials & Insights - Benzinga España

What date does Acurx Pharmaceuticals's (ACXP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research

Clostridium Difficile Infections Market Forecast Signals - openPR.com

ACXP Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Gains on Operational Updates - dars.gov.et

Price to book forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView

Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView

Price to book forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView

Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView

Price to earnings forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView

Price to earnings forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView

Acurx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ACXP) - TradingView

ACXP Forecast — Price Target — Prediction for 2027 - tradingview.com

Price to book forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く